Com­pu­gen se­cures li­cens­ing deal with Gilead for IL-18 pro­tein an­ti­body can­cer pro­gram, with $60M up­front

Com­pu­gen is set to re­ceive an up­front pay­ment of $60 mil­lion from Gilead to kick­start an ex­clu­sive li­cens­ing deal for the biotech’s an­ti-in­ter­leukin-18 pro­tein bind­ing an­ti­body pro­gram for sol­id tu­mors, in­clud­ing the pre­clin­i­cal can­di­date COM503.

Ac­cord­ing to the com­pa­nies, the li­cens­ing deal is worth $848 mil­lion, with Com­pu­gen set to re­ceive an ad­di­tion­al $30 mil­lion next year if COM503 se­cures an IND and a fur­ther $758 mil­lion in to­tal that cov­ers fu­ture de­vel­op­ment, reg­u­la­to­ry and com­mer­cial mile­stones. Al­so in store for Com­pu­gen are “sin­gle-dig­it to low dou­ble-dig­it tiered roy­al­ty pay­ments” for net sales world­wide.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER